The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis

Massimo Minozzi, S. Gerli, G. C. Di Renzo, E. Papaleo, A. Ferrari

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: At the present the clinical treatment of choice of bacterial vaginosis (BV) is the use of systemic or local metronidazole or clindamycin. Aim of the study was to evaluate the efficacy and tolerability of a single dose of gynaecolodic solution, Polyhexamiethylene Biguanide (PHMB), Monogin®, in the treatment of BV in comparison to a 7-days treatment with clindamycin vaginal cream. Study Design: This multicenter, randomized, single-blind, parallel-group study enrolled 740 patients with BV infections. Treatment consisted of either a single intravaginal dose of PHMB or 7 daily doses of Clindamycin. Efficacy and safety were assessed 21-30 days after the start of treatment. The efficacy endpoints were Investigator Cure, Clinical Cure (a composite of all 4 Amsel's criteria and investigator Cure), Nugent Cure (Nugent score <4), and therapeutic cure (a composite of clinical cure and Nugent Cure). Resolution of individual Amsel's criteria was also evaluated. Any adverse event of the treatment has been monitored throughout the study. Results. No significant differences has been reported in cure rates between the PHMB and Clindamycin treatment groups in Investigator Cure (P = 0.702), Clinical Cure (P = 0.945), Nugent Cure (P = 0.788), or Therapeutic Cure (P = 0.572). Results were also similar for 3 of 4 and 2 of 4 Amsel's criteria and for each individual Amsel's criterion (all P-values > 0.200). Ninety-five percent confidence intervals for each endpoint were consistent with equivalence between the 2 products. There was no significant difference between the treatment groups in the incidence of treatment-emergent adverse events (P = 0.386). Conclusions: A single dose, of PHMB gynaecologic solution (Monogin®) is equivalent in safety and efficacy to a 7-dose regimen of Clindamycin vaginal cream in the treatment of bacterial vaginosis. Futhermore the compliance as been reported to be higher for the single-dose treatment with PHMB than with 7-days treatment with Clindamycin.

Original languageEnglish
Pages (from-to)59-65
Number of pages7
JournalEuropean Review for Medical and Pharmacological Sciences
Volume12
Issue number1
Publication statusPublished - Jan 2008

Fingerprint

Foams and Jellies Vaginal Creams
Bacterial Vaginosis
Clindamycin
Safety
Biguanides
Therapeutics
Research Personnel
polyhexamethylene biguanide
Metronidazole
Bacterial Infections
Compliance

Keywords

  • Bacterial vaginosis
  • Clindamycin vaginal cream
  • PHMB
  • Vaginitis

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{60312ddaa97f43b8a42064f00c28f49c,
title = "The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis",
abstract = "Objective: At the present the clinical treatment of choice of bacterial vaginosis (BV) is the use of systemic or local metronidazole or clindamycin. Aim of the study was to evaluate the efficacy and tolerability of a single dose of gynaecolodic solution, Polyhexamiethylene Biguanide (PHMB), Monogin{\circledR}, in the treatment of BV in comparison to a 7-days treatment with clindamycin vaginal cream. Study Design: This multicenter, randomized, single-blind, parallel-group study enrolled 740 patients with BV infections. Treatment consisted of either a single intravaginal dose of PHMB or 7 daily doses of Clindamycin. Efficacy and safety were assessed 21-30 days after the start of treatment. The efficacy endpoints were Investigator Cure, Clinical Cure (a composite of all 4 Amsel's criteria and investigator Cure), Nugent Cure (Nugent score <4), and therapeutic cure (a composite of clinical cure and Nugent Cure). Resolution of individual Amsel's criteria was also evaluated. Any adverse event of the treatment has been monitored throughout the study. Results. No significant differences has been reported in cure rates between the PHMB and Clindamycin treatment groups in Investigator Cure (P = 0.702), Clinical Cure (P = 0.945), Nugent Cure (P = 0.788), or Therapeutic Cure (P = 0.572). Results were also similar for 3 of 4 and 2 of 4 Amsel's criteria and for each individual Amsel's criterion (all P-values > 0.200). Ninety-five percent confidence intervals for each endpoint were consistent with equivalence between the 2 products. There was no significant difference between the treatment groups in the incidence of treatment-emergent adverse events (P = 0.386). Conclusions: A single dose, of PHMB gynaecologic solution (Monogin{\circledR}) is equivalent in safety and efficacy to a 7-dose regimen of Clindamycin vaginal cream in the treatment of bacterial vaginosis. Futhermore the compliance as been reported to be higher for the single-dose treatment with PHMB than with 7-days treatment with Clindamycin.",
keywords = "Bacterial vaginosis, Clindamycin vaginal cream, PHMB, Vaginitis",
author = "Massimo Minozzi and S. Gerli and {Di Renzo}, {G. C.} and E. Papaleo and A. Ferrari",
year = "2008",
month = "1",
language = "English",
volume = "12",
pages = "59--65",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "1",

}

TY - JOUR

T1 - The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis

AU - Minozzi, Massimo

AU - Gerli, S.

AU - Di Renzo, G. C.

AU - Papaleo, E.

AU - Ferrari, A.

PY - 2008/1

Y1 - 2008/1

N2 - Objective: At the present the clinical treatment of choice of bacterial vaginosis (BV) is the use of systemic or local metronidazole or clindamycin. Aim of the study was to evaluate the efficacy and tolerability of a single dose of gynaecolodic solution, Polyhexamiethylene Biguanide (PHMB), Monogin®, in the treatment of BV in comparison to a 7-days treatment with clindamycin vaginal cream. Study Design: This multicenter, randomized, single-blind, parallel-group study enrolled 740 patients with BV infections. Treatment consisted of either a single intravaginal dose of PHMB or 7 daily doses of Clindamycin. Efficacy and safety were assessed 21-30 days after the start of treatment. The efficacy endpoints were Investigator Cure, Clinical Cure (a composite of all 4 Amsel's criteria and investigator Cure), Nugent Cure (Nugent score <4), and therapeutic cure (a composite of clinical cure and Nugent Cure). Resolution of individual Amsel's criteria was also evaluated. Any adverse event of the treatment has been monitored throughout the study. Results. No significant differences has been reported in cure rates between the PHMB and Clindamycin treatment groups in Investigator Cure (P = 0.702), Clinical Cure (P = 0.945), Nugent Cure (P = 0.788), or Therapeutic Cure (P = 0.572). Results were also similar for 3 of 4 and 2 of 4 Amsel's criteria and for each individual Amsel's criterion (all P-values > 0.200). Ninety-five percent confidence intervals for each endpoint were consistent with equivalence between the 2 products. There was no significant difference between the treatment groups in the incidence of treatment-emergent adverse events (P = 0.386). Conclusions: A single dose, of PHMB gynaecologic solution (Monogin®) is equivalent in safety and efficacy to a 7-dose regimen of Clindamycin vaginal cream in the treatment of bacterial vaginosis. Futhermore the compliance as been reported to be higher for the single-dose treatment with PHMB than with 7-days treatment with Clindamycin.

AB - Objective: At the present the clinical treatment of choice of bacterial vaginosis (BV) is the use of systemic or local metronidazole or clindamycin. Aim of the study was to evaluate the efficacy and tolerability of a single dose of gynaecolodic solution, Polyhexamiethylene Biguanide (PHMB), Monogin®, in the treatment of BV in comparison to a 7-days treatment with clindamycin vaginal cream. Study Design: This multicenter, randomized, single-blind, parallel-group study enrolled 740 patients with BV infections. Treatment consisted of either a single intravaginal dose of PHMB or 7 daily doses of Clindamycin. Efficacy and safety were assessed 21-30 days after the start of treatment. The efficacy endpoints were Investigator Cure, Clinical Cure (a composite of all 4 Amsel's criteria and investigator Cure), Nugent Cure (Nugent score <4), and therapeutic cure (a composite of clinical cure and Nugent Cure). Resolution of individual Amsel's criteria was also evaluated. Any adverse event of the treatment has been monitored throughout the study. Results. No significant differences has been reported in cure rates between the PHMB and Clindamycin treatment groups in Investigator Cure (P = 0.702), Clinical Cure (P = 0.945), Nugent Cure (P = 0.788), or Therapeutic Cure (P = 0.572). Results were also similar for 3 of 4 and 2 of 4 Amsel's criteria and for each individual Amsel's criterion (all P-values > 0.200). Ninety-five percent confidence intervals for each endpoint were consistent with equivalence between the 2 products. There was no significant difference between the treatment groups in the incidence of treatment-emergent adverse events (P = 0.386). Conclusions: A single dose, of PHMB gynaecologic solution (Monogin®) is equivalent in safety and efficacy to a 7-dose regimen of Clindamycin vaginal cream in the treatment of bacterial vaginosis. Futhermore the compliance as been reported to be higher for the single-dose treatment with PHMB than with 7-days treatment with Clindamycin.

KW - Bacterial vaginosis

KW - Clindamycin vaginal cream

KW - PHMB

KW - Vaginitis

UR - http://www.scopus.com/inward/record.url?scp=41149166710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149166710&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 59

EP - 65

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 1

ER -